• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·UK·Healthcare·HIK.L
Share

Hikma Pharmaceuticals PLC Stocks

£ 1615Last Updated 09.07.2026

Issuer Rating

7/7
Performance

Strong

Risk

Low

Recommendation

Buy

Market Cap

£ 4.35B

£ 1615
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Hikma Pharmaceuticals PLC is a global pharmaceutical enterprise involved in the creation, production, promotion, and distribution of a wide array of generic, branded, and licensed medicinal solutions. These offerings are presented in various dosage formats, including solid, semi-solid, liquid, and injectable forms. The company's operations are strategically structured into three core segments: Injectables, Generics, and Branded. The Injectables division specializes in providing generic injectable medications, predominantly for hospital environments. Conversely, the Generics segment is responsible for supplying oral and other non-injectable generic pharmaceuticals to the consumer retail market. The Branded unit caters to both retail and hospital clients with its proprietary generic and in-licensed products. Hikma's comprehensive product portfolio addresses a broad spectrum of medical conditions, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory ailments. The firm boasts a substantial international presence, conducting business across the United Kingdom, the United States, the Middle East, North Africa, and various European countries. Founded in 1978, the company's corporate headquarters are situated in London, United Kingdom.

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, neutral on EV

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of HIK.L is 2010 and suggests 23.1% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

11.07.2026 01:30

User-generated content is Reddit's advantage in the age of AI, according to an analyst

11.07.2026 01:21

SK Hynix's First Day of Trading in the U.S. and Meta's Surge: The Market Bet on AI on Friday

11.07.2026 00:31

Meta Shares Are on Track for Their Best Weekly Performance in 2.5 Years Thanks to New AI

10.07.2026 23:06

Delta's profits were eaten up by record fuel costs. But revenue was buoyed by demand

10.07.2026 21:56

An Unwelcome Measure: Why Kazakhstan Is Abolishing the Mandatory Sale of Foreign Currency Proceeds

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026